3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Neuroendocrine Tumors
13
Carcinoid Tumor
5
Gastro-enteropancreatic neuroendocrine tumor
4
Acromegaly
4
Serotonin Syndrome
2
Pituitary Neoplasms
2
Neoplasm Metastasis
2
Prostatic Neoplasms
1
Pheochromocytoma
1
Peritoneal Neoplasms
1
Paraganglioma
1
Pancreatic Neoplasms
1
Neuroendocrine Tumour With Carcinoid Symptoms
1
Neuroendocrine Tumors in Lung
1
Neoplasms
1
Intestinal Obstruction
1
Growth Hormone-Secreting Pituitary Adenoma
1
Gigantism
1
Gastrointestinal Neoplasms
1
Flushing
1
Endocrine Tumors
1
Diarrhea
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Carcinoma
1
Carcinoid Heart Disease
1
Adenoma, Islet Cell
1
Interventions
Everolimus
8
Temozolomide
7
Sunitinib
6
Specimen Handling
4
Octreotide
4
Magnetic Resonance Spectroscopy
4
Fluorouracil
4
Capecitabine
4
lutetium Lu 177 dotatate
3
Leucovorin
3
sargramostim
2
montanide ISA 51
2
incomplete Freund's adjuvant
2
cabozantinib
2
Thalidomide
2
Streptozocin
2
Oxaliplatin
2
Irinotecan
2
Injections
2
Doxorubicin
2
Cytoreduction Surgical Procedures
2
Colony-Stimulating Factors
2
Bevacizumab
2
surufatinib
1
sapanisertib
1
recombinant interferon alpha 2b-like protein
1
pentetreotide
1
pasireotide
1
nimotuzumab
1
napabucasin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Adenoma, Islet Cell
×
lanreotide
×
Clear all
NCT05477576
2026-03-30
ACTION-1
RayzeBio, Inc.
Phase 3
Recruiting
338 enrolled